Meningiomas are usually considered benign brain tumors, however, up to one-third can display an aggressive behavior resulting in recurrence and accelerated tumor growth. The treatment consists of surgical resection and/or radiotherapy. However, to date, there are no systemic treatment options for patients.
In this project, we will explore the pharmacological landscape of aggressive meningiomas by using an automated drug screening platform and mini-tumors derived from freshly resected meningioma tissue. Thereafter, the most effective drugs will be further characterized based on the mode of action and resistance mechanism. The aim of the project is to tailor more effective therapies for meningioma patients.
Here you can find further information.